{
    "clinical_study": {
        "@rank": "159770", 
        "acronym": "SAVED-P", 
        "arm_group": [
            {
                "arm_group_label": "Cholecalciferol 4000 IU", 
                "arm_group_type": "Experimental", 
                "description": "Cholecalciferol 4000 IU oral chewable tablet once daily for 8 weeks"
            }, 
            {
                "arm_group_label": "Cholecalciferol 2000 IU", 
                "arm_group_type": "Experimental", 
                "description": "Cholecalciferol 2000 IU oral chewable tablet once daily for 8 weeks"
            }, 
            {
                "arm_group_label": "Cholecalciferol 200 IU", 
                "arm_group_type": "Active Comparator", 
                "description": "Cholecalciferol 200 IU oral chewable tablet once daily for 8 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This study of vitamin D is designed to assess both the safety and efficacy of potential\n      doses (2,000 IU/day and 4,000 IU/day) in raising a vitamin D level to a normal range in a\n      short period of time (e.g. 4 weeks or less) compared to 200 IU/day.\n\n      In children with vitamin D insufficiency or deficiency who are at risk for severe asthma\n      exacerbations, we hypothesize that both vitamin D supplementation with 4,000 IU/day and\n      2,000 IU/day will safely achieve normal vitamin D levels, but that the higher dose (4,000\n      IU/day) will result in a larger proportion of subjects achieving this level within 4 weeks."
        }, 
        "brief_title": "Vitamin D and Severe Asthma Exacerbations", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "detailed_description": {
            "textblock": "Asthma is a major public health problem in the United States and worldwide. Severe disease\n      exacerbations account for the majority of costs attributable to asthma in the United States.\n       Vitamin D is an essential nutrient with significant immuno-modulatory effects. The\n      observation that vitamin D insufficiency and asthma share risk factors such as urban\n      residence, obesity, and African American ethnicity has generated significant interest in\n      exploring a link between these two conditions.\n\n      This is an 8-week randomized, double-masked, controlled trial of vitamin D3 (2,000 IU/day\n      and 4,000 IU/day) to achieve vitamin D sufficiency (a serum 25(OH)D \u226530 ng/ml in 60\n      school-aged children (ages 6 to 14 years) who have vitamin D insufficiency (a serum 25(OH)D\n      <30 ng/ml) and are at risk for severe asthma exacerbations, but whose asthma that is\n      well-controlled on medium-dose inhaled corticosteroid (ICS) at the end of a 4-week run-in\n      period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Be at least 6 years of age and younger than 15 years of age\n\n          -  Have physician-diagnosed asthma\n\n          -  Taking a medium dose of ICS (e.g. fluticasone 220mcg BID) for daily asthma control\n             for at least 6 months in the prior year.\n\n          -  Have had a severe asthma exacerbation in the previous year, defined as an Emergency\n             Department (ED) visit, hospitalization, or unscheduled clinic visit for asthma\n             resulting in intramuscular, intravenous, or oral steroids.\n\n          -  Have bronchodilator responsiveness (BDR, an increase in FEV1 \u226512% from baseline after\n             administration of inhaled albuterol) or (if no BDR) increased airway responsiveness\n             to methacholine challenge\n\n          -  Have vitamin D insufficiency (a serum vitamin D (25(OH)D) level <30 ng/ml)\n\n          -  Have his/her parents give voluntary written consent to participate in the study\n\n        Exclusion Criteria:\n\n          -  Chronic respiratory disorder other than asthma (e.g., bronchiectasis).\n\n          -  Severe asthma, as evidenced by any of the following: a) chronic need for medication\n             other than single controller therapy and inhaled  \u03b22-agonist, b) intubation for\n             asthma at any time, and c) \u22652 hospitalizations or \u22656 severe asthma exacerbations in\n             the previous year\n\n          -  History of cigarette smoking in the prior year or former smoking if \u22655 pack-years\n\n          -  Hepatic or renal disease, metabolic rickets, malabsorptive disorders, or other\n             chronic diseases that would affect vitamin D metabolism\n\n          -  Immune deficiency, cleft palate or Down's syndrome, which might increase the child's\n             likelihood of respiratory infections\n\n          -  Treatment with anticonvulsants or pharmacological doses of vitamin D (\u22651,000 IU/day\n             of vitamin D2 or D3)\n\n          -  Chronic oral corticosteroid therapy\n\n          -  Inability to perform acceptable spirometry\n\n          -  Use of investigational therapies or participation in clinical trials 30 days before\n             or during the duration of the study\n\n          -  Serum calcium >10.8 mg/dl\n\n          -  Serum 25(OH) D <10 ng/ml (severe vitamin D deficiency)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "14 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01921894", 
            "org_study_id": "SAVED-P"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cholecalciferol 4000 IU", 
                "Cholecalciferol 2000 IU", 
                "Cholecalciferol 200 IU"
            ], 
            "intervention_name": "Cholecalciferol", 
            "intervention_type": "Dietary Supplement", 
            "other_name": "vitamin D3"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cholecalciferol", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "asthma", 
            "vitamin D"
        ], 
        "lastchanged_date": "August 9, 2013", 
        "location": {
            "contact": {
                "email": "rose.lanzo@chp.edu", 
                "last_name": "Rose Lanzo, BS, RT", 
                "phone": "412-692-5872"
            }, 
            "contact_backup": {
                "email": "elizabeth.hartigan@chp.edu", 
                "last_name": "Elizabeth R Hartigan, RN, MPH", 
                "phone": "412-692-7060"
            }, 
            "facility": {
                "address": {
                    "city": "Pittsburgh", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "15224"
                }, 
                "name": "Children's Hospital of Pittsburgh of UPMC"
            }, 
            "investigator": {
                "last_name": "Juan C Celedon, M.D., Dr.P.H.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase I Trial for Children With Vitamin D Insufficiency and High Risk of Severe Asthma Exacerbations", 
        "overall_contact": {
            "email": "rose.lanzo@chp.edu", 
            "last_name": "Rose Lanzo, BS, RT", 
            "phone": "412-692-5872"
        }, 
        "overall_contact_backup": {
            "email": "elizabeth.hartigan@chp.edu", 
            "last_name": "Elizabeth R Hartigan, RN, MPH", 
            "phone": "412-692-7060"
        }, 
        "overall_official": {
            "affiliation": "University of Pittsburgh", 
            "last_name": "Juan C Celedon, M.D., Dr.P.H.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome of the proposed trial will be a sufficient (\u226530 ng/ml) vitamin D level after 4 weeks of supplementation", 
            "measure": "Vitamin D level", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01921894"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "to both monitor for vitamin D toxicity and assess the stability of vitamin D levels after supplementation with the two different intervention doses.", 
                "measure": "Vitamin D levels", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "to assess safety by monitoring     for Vitamin D toxicity", 
                "measure": "Urinary calcium/creatinine ratio", 
                "safety_issue": "Yes", 
                "time_frame": "4 and 8 weeks"
            }, 
            {
                "description": "Forced expiratory volume in 1 second (FEV1) as percent predicted (with reference values used according to the child's age, gender and ethnicity) and FEV1/FVC (forced vital capacity) (adjusted for age and sex), and bronchodilator responsiveness (BDR, expressed as a percentage of the baseline FEV1 [\u2206FEV1=[(post-bronchodilator FEV1 - baseline FEV1)/baseline FEV1] x 100).", 
                "measure": "Measures of lung function", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "source": "University of Pittsburgh", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Pittsburgh", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}